RDHL · Redhill Biopharma Ltd. American Depositary Shares
View on chartInsiders & Stakes
| Gilead Raday Chief Operating Officer | ▼ Sell | Open Market | 176,910,000 Shares held | 10/1/2026 | View profile |
Transaction History
| Gilead Raday | ▼ Sell | Open Market | 14,310,000 | $1K | 10/1/2026 |
| Gilead Raday | ▼ Sell | Open Market | 14,130,000 | $1K | 7/10/2026 |
| Gilead Raday | ▼ Sell | Open Market | 15,740,000 | $2K | 4/6/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
RedHill Biopharma reports zero revenue and EPS for H1 2026
RedHill Biopharma announced its first half 2026 financial results, reporting zero revenue and zero earnings per share. The company also shared operational highlights alongside these figures. This report provides a snapshot of the company's current financial position, noting that it generated no income during this period.
RedHill Biopharma reports zero revenue and EPS for H1 2026. RedHill Biopharma announced its first half 2026 financial results, reporting zero revenue and zero earnings per share. The company also shared operational highlights alongside these figures. This report provides a snapshot of the company's current financial position, noting that it generated no income during this period.